IMMUSE proactively supports the immune system through a novel method of action that activates plasmacytoid dendritic cells (pDCs)
Kyowa Hakko has announced its IMMUSE postbiotic for immune health has been named as one of three finalists in the Ingredient of the Year: Microbiome Modulation category of the NutraIngredients-USA Awards.
As a clinically researched immune activator supported by 30 published studies, including 15 human trials, IMMUSE proactively supports the immune system through a novel method of action that activates plasmacytoid dendritic cells (pDCs). This mechanism of action was discovered by Kyowa Hakko’s parent company, Kirin Holdings.
“Consumers are taking more responsibility for their health and educating themselves on the ingredients in their supplements, so many already understand that pDCs are some of the key leaders of our immune system,” said Karen Todd, VP at Kyowa Hakko USA. “A rare type of immune cell, pDCs have been shown to activate other cells pivotal to immune health such as NK, Killer-T, Helper-T, and B cells for a more comprehensive approach to immune support. IMMUSE is the only strain of lactococcus lactis on the market that targets pDCs.”
The NutraIngredients-USA nomination is not the first time IMMUSE has been recognised in industry. Natural Products Insider also named IMMUSE as a Best-In-Class Ingredient at the 2021 SupplySide West Ingredient Idol competition and Frost & Sullivan recognised the ingredient with its 2021 North American New Product Innovation Award.
“We are so proud and appreciative that esteemed organisations within the industry see IMMUSE’s potential to shape the future of health and wellness,” Todd said.
Due to its stable nature, long shelf life, and flexible formulation, IMMUSE can be used in a variety of applications, including your next powder or capsule. The ingredient opens new doors for immune support in product categories ranging from daily wellness to sports nutrition.